Location:Home /  Resource
Past list
COVID-19 Webinar Series: The use of MGI sequencing platform in a translational response against COVID-19
Release date:2021-05-21Writer:MGIViews:2470Share
The dynamics underlying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) re-infection remain poorly understood. We identified a small cluster of individuals with two episodes of 2019 coronavirus disease (COVID-19) in March and late May of 2020. In the first episode, individuals presented an enhanced innate response compared to healthy individuals, but neutralizing humoral immunity was not fully achieved. The second episode was associated with different SARS-CoV-2 strains, higher viral loads, and clinical symptoms. The identification that some individuals with mild COVID-19 may have controlled SARS-CoV-2 replication without developing detectable humoral immunity raises the possibility that re-infection is more frequent than supposed, but weakly documented.
Dr. Thiago Moreno L. Souza

National Institute of Science and Technology for Innovation on Neglected Population Diseases (INCT-IDPN), and Oswaldo Cruz Institute, Immunopharmacology Laboratory, Rio de Janeiro, RJ, Brazil

If you have any questions, you can send an email to:
  • Hotline (Global)
  • Email
  • Special Recommendations
  • *For research use only.

    Not for use in diagnostic procedures (except as specifically noted).
Copyright © 2024 All Rights Reserved MGI Tech Co., Ltd. Guangdong ICP 16117185Privacy PolicyLegal NoticesCookie Policy
Our use of cookies
We would like to use necessary cookies to improve your browsing experience and the quality of our website. We would also like to set analytics cookies and advertisement cookies that help us make improvements by measuring how you use our website. Detailed information about the use of cookies on this website and how you can control your consent can be found in our Cookie Policy and Privacy Policy.
Accept only strictly necessary cookiesAccept all cookies